Miles CM Chen

CEO
Fecula Biotech Co., Ltd.
​`

Miles is the Chief Executive Officer of Fecula Biotech Corporation (FBC). In this role, he is responsible for creating, planning, implementing, and integrating the strategic direction of FBC, with the goal of increasing shareholder value.
Previously, Miles served as the CEO of Golden Biotechnology Corporation, a publicly listed company in Taiwan. Prior to that, he was Head of the R&D Department at Golden Biotechnology and a research fellow at Academia Sinica in Taiwan.
Miles has more than 18 years of experience in drug discovery research, including the preclinical and clinical development of drug candidates.
Currently, in addition to his role as CEO, Miles also advises on the development of microbiome-related therapeutic drugs and functional foods at FBC.
He holds a PhD in Biotechnology from National Chung Hsing University and completed his postdoctoral research at the Biodiversity Research Center, the Genomic Research Center, and the Institute of Biological Chemistry at Academia Sinica, Taiwan.​

Speech title & Synopsis

Company Profile

Fecula Biotech Co., Ltd. was established in February 2019. The headquarters is located in the SME Incubator Center at the Southern Taiwan Science Park. In 2020, the company received funding from the National Development Fund’s Startup Angel Project. In 2022, it was listed on the TPEx Go Incubation Board for Startups and Acceleration Firms (GISA) with the stock code 7627 and a paid-in capital of NTD 35 million.
Our mission is to develop innovative and efficient approaches to address the growing issue of agricultural waste, transforming it into eco-efficient and sustainable product opportunities that benefit the environment, the economy, and consumers. We have successfully converted agro-waste—such as bananas, Citrus depressa Hayata, strawberry leaves, and fish scales—into functional food ingredients and dietary supplement products. Furthermore, strawberry leaf extract has been successfully developed as a cosmetic ingredient, and clinical studies have shown visible improvements in skin brightness, moisture, and elasticity.
Our core technology is the Resistant Starch-Based Encapsulation Technique (RS-BET), which utilizes banana-resistant starch as a building block. This innovative approach can be applied to the development of pharmaceuticals and supplements, depending on the specific characteristics of the resistant starch. Through the synergistic combination of probiotics and novel agricultural resources, we have successfully launched microbiota-related (probiotic) dietary supplements, which have gained a global market presence.
In addition to our current achievements, we are actively engaged in the development of microbiome-based therapeutics and vaccines, utilizing our core RS-BET technology. Our pipeline includes the following projects:
(1) Oral delivery of a pancreatic cancer vaccine
(2) Oral fecal microbiota transplantation (FMT) capsules for cancer adjuvant therapy
(3) A botanical drug for the inhibition of cancer invasion and metastasis
As a company, we are committed to transforming agricultural waste into valuable bioproducts, aligning with the principles of sustainable development and the circular economy. We aim to create a positive impact on both the environment and society.